Journal
SCIENCE
Volume 329, Issue 5998, Pages 1537-1541Publisher
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/science.1193692
Keywords
-
Categories
Funding
- CNRS
- ANR
- INSERM
Ask authors/readers for more resources
The serotonin transporter (SERT) ensures the recapture of serotonin and is the pharmacological target of selective serotonin reuptake inhibitor (SSRI) antidepressants. We show that SERT is a target of microRNA-16 (miR-16). miR-16 is expressed at higher levels in noradrenergic than in serotonergic cells; its reduction in noradrenergic neurons causes de novo SERT expression. In mice, chronic treatment with the SSRI fluoxetine (Prozac) increases miR-16 levels in serotonergic raphe nuclei, which reduces SERT expression. Further, raphe exposed to fluoxetine release the neurotrophic factor S100 beta, which acts on noradrenergic cells of the locus coeruleus. By decreasing miR-16, S100 beta turns on the expression of serotonergic functions in noradrenergic neurons. Based on pharmacological and behavioral data, we propose that miR-16 contributes to the therapeutic action of SSRI antidepressants in monoaminergic neurons.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available